The strategic approach of Marksans centres on the integration and utilization of company strengths to propel growth. Our primary expertise lies in proactively addressing and meeting the rising demands of our clients, positioning us as the preferred business partner.

From the Chairman's Desk

Leveraging Our Strengths

  • Diverse product portfolio of tablets (plain, enteric-coated, and film-coated), hard capsules, soft gelatin capsules, oral liquids, and ointments
  • FDA, TGA, MHRA-approved facility with the largest capacity of soft gelatin formulations in India
  • Manufactures more than 1,500 SKUs and 300+ products
  • Export to Regulated markets – USA, Europe, Australia, and Canada to drive profits
  • Strong R&D capabilities
  • Adding new capacity of 8 billion units per annum in new low-cost manufacturing capabilities

Our Strategic Initiatives

  • Rapid filing of ANDAs/ MAs in the US, Europe, and the emerging markets
  • Backward Integration for sustained margin development through CDMO strategy
  • Investing in new low-cost manufacturing capabilities
  • Supplement growth through acquisitions
  • Continued product launches through a healthy product pipeline
From the Chairman's Desk
Marksans Pharma Ltd

Focus Areas - Europe, US & Emerging Markets

  • Leveraging our state-of-the-art infrastructure to become a preferred manufacturing and distribution partner in regulated markets
  • Establishing a strong presence in the US generic pharmaceutical market
  • Focussing on building IP assets, especially in the niche dosage forms
  • Out-licensing IP to drive growth/ scalability
  • Building and launching portfolios of generic products in niche segments, technology-driven products (also seeking newer potential markets)
  • Building significant OTC presence across the regulated markets